Abstract
In this review, the potential of pharmacologic therapy for prevention of radiation-induced bone growth inhibition is discussed. Significant radioprotection using the radioprotector Amifostine has been achieved in animal models of radiation-induced retardation of long and craniofacial bone growth. Moreover, radioprotection in vitro has been achieved in a number of cell lines, including osteoblast-like, endothelial, and fibroblastic. This evidence may support future clinical investigations of radioprotector Amifostine or similar substances for radioprotection of the growing craniofacial skeleton.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amifostine / metabolism
-
Amifostine / pharmacology*
-
Animals
-
Bone and Bones / drug effects
-
Bone and Bones / radiation effects
-
Cell Line / drug effects
-
Cell Line / radiation effects
-
Facial Bones / drug effects*
-
Facial Bones / growth & development
-
Facial Bones / radiation effects
-
Growth / radiation effects
-
Models, Animal
-
Radiation Injuries, Experimental / prevention & control
-
Radiation Protection / methods*
-
Radiation-Protective Agents / metabolism
-
Radiation-Protective Agents / pharmacology*
-
Radiotherapy / adverse effects
Substances
-
Radiation-Protective Agents
-
Amifostine